CARbon monoxidE intoxiCatiOn in Korea: Prospective Cohort (CARE CO Cohort)
Carbon Monoxide Poisoning · Myocardial Injury · Neurologic Deficits · Image, Body · Therapy · Prognostic Factors · Complications
What this study involves
The registry says this study is recruiting. Individual locations may have different availability.
- Study type
- Observational
- Phase
- Not applicable / not listed
- Age range
- Not specified - Not specified
- Sex eligible
- All sexes
- Healthy volunteers
- Not accepted
- Participants
- 1500 Estimated
These are starting points, not an eligibility decision. The research team must review the full requirements.
About the research
This prospective cohort study enrolls subjects who experience carbon monoxide (CO) poisoning. The purpose of the study is to evaluate therapeutic effects of various treatments and short and long-term outcomes in CO poisoned patients. In addition, complications of brain and heart susceptible to CO are investigated through various ways and the association between complications and the patient's prognosis is also investigated. All subjects will be regularly monitored by physicians participating in this study.
Read the full description
This prospective cohort study enrolls subjects who experience CO poisoning. The purpose of the study is to evaluate therapeutic effects of various treatments, including hyperbaric oxygen therapy (HBO), therapeutic hypothermia (TH), and additional drugs, and short and long-term outcomes, such as neurocognitive sequelae or mortality, in CO poisoned patients. In addition, complications of brain and heart susceptible to CO are investigated through a variety of ways, such as magnetic resonance image (MRI), computed tomography (CT), ultrasound, and laboratory test, and the association between various complications and the patient's prognosis is also investigated. All subjects will be regularly monitored by physicians participating in this study.
Who may be able to participate?
The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.
Inclusion Criteria:
- Acute CO poisoning
Exclusion Criteria:
- Declined to enrollment in the study
Study population
Acute CO poisoning
Understand screeningTreatment, groups and participation
The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.
- Assignment
- Not reported
- Masking
- Not reported
Acute CO poisoning
A diagnosis of CO poisoning is made according to medical history and carboxyhemoglobin \>5% (\>10% in smokers).
Diagnostic Test: Cardiac MRI · Procedure: Hyperbaric oxygen therapy
Cardiac MRI DIAGNOSTIC_TEST
1. Cardiac MRI be taken to CO poisoned patients
2. Cardiac CT be taken to CO poisoned patients
3. TTE be taken to CO poisoned patients
4. Brain MRI be taken to CO poisoned patients
5. Neurocognitive function tests be taken to CO poisoned patients
6. Laboratory tests be taken to CO poisoned patients
Hyperbaric oxygen therapy PROCEDURE
1. Hyperbaric oxygen therapy be used for CO poisoned patients
2. Therapeutic hypothermia be used for CO poisoned patients
What researchers are measuring
Outcome measures describe what is being studied. They are not proof that a treatment works.
Primary measures
Therapeutic response to HBO at 1 month
Time frame: At 1 month after CO exposure
Therapeutic response to HBO according to times from rescue to first HBO and frequency and pressure of HBO at 1 month after CO exposure
Therapeutic response to HBO at 6 months
Time frame: At 6 months after CO exposure
Therapeutic response to HBO according to times from rescue to first HBO and frequency and pressure of HBO at 6 months after CO exposure
Predictors and model development for participants with poor outcome including mortality, and neurocognitive and psychological sequelae at 1 month after CO exposure evaluated by such as neurocognitive function tests
Time frame: Within 1 month after CO exposure
Predictors and model development for poor outcome including mortality, and neurocognitive and psychological sequelae at 1 month after CO exposure evaluated by tools, such as global deterioration scale (GDS) or Carbon Monoxide Neuropsychological Screening Battery (CONSB), etc, through variables, such as clinical features, laboratory tests, or imaging study that can be investigated within 1 month
Predictors and model development for participants with poor outcome including mortality, and neurocognitive and psychological sequelae at 6 months after CO exposure evaluated by such as neurocognitive function tests
Time frame: Within 1 month after CO exposure
Predictors and model development for poor outcome including mortality, and neurocognitive and psychological sequelae at 6 months after CO exposure evaluated by tools, such as global deterioration scale (GDS) or Carbon Monoxide Neuropsychological Screening Battery (CONSB), etc, through variables, such as clinical features, laboratory tests, or imaging study that can be investigated within 1 month
Predictors and model development for participants with poor outcome including mortality, and neurocognitive and psychological sequelae at 12 months after CO exposure evaluated by such as neurocognitive function tests
Time frame: Within 1 month after CO exposure
Predictors and model development for poor outcome including mortality, and neurocognitive and psychological sequelae at 12 months after CO exposure evaluated by tools, such as global deterioration scale (GDS) or Carbon Monoxide Neuropsychological Screening Battery (CONSB), etc, through variables, such as clinical features, laboratory tests, or imaging study that can be investigated within 1 month
Secondary measures
Therapeutic response to HBO at 12 months
Time frame: At 12 months after CO exposure
Therapeutic response to HBO according to times from rescue to first HBO and frequency and pressure of HBO at 12 months after CO exposure
Therapeutic response to TH combined with HBO at 1 month
Time frame: At 1 month after CO exposure
Therapeutic response to TH combined with HBO in acute severe CO poisoning at 1 month after CO exposure
Therapeutic response to TH combined with HBO at 6 months
Time frame: At 6 months after CO exposure
Therapeutic response to TH combined with HBO in acute severe CO poisoning at 6 months after CO exposure
Therapeutic response to TH combined with HBO at 12 months
Time frame: At 12 months after CO exposure
Therapeutic response to TH combined with HBO in acute severe CO poisoning at 12 months after CO exposure
Therapeutic response to HBO according to presence of apolipoprotein E4 at 1 month
Time frame: At 1 month after CO exposure
Therapeutic response to HBO according to presence of apolipoprotein E4 genotype at 1 month after CO exposure
Therapeutic response to HBO according to presence of apolipoprotein E4 at 6 months
Time frame: At 6 months after CO exposure
Therapeutic response to HBO according to presence of apolipoprotein E4 genotype at 6 months after CO exposure
Therapeutic response to HBO according to presence of apolipoprotein E4 at 12 months after CO exposure
Time frame: At 12 months after CO exposure
Therapeutic response to HBO according to presence of apolipoprotein E4 genotype at 12 months after CO exposure
Cardiac injury evaluated by cardiac MRI in acute phase
Time frame: Within 1 month after CO exposure
Cardiac injury related to CO poisoning evaluated by cardiac MRI in acute phase
Cardiac injury evaluated by cardiac MRI in chronic phase
Time frame: Follow-up cardiac MRI (at 4-8 months after CO exposure)
Cardiac injury related to CO poisoning evaluated by cardiac MRI in chronic phase
Cardiac injury evaluated by cardiac CT
Time frame: Within 1 month after CO exposure
Cardiac injury evaluated by cardiac CT in CO poisoning
Cardiac injury evaluated by TTE in acute phase
Time frame: Within 14 days after CO exposure
Cardiac injury related to CO poisoning evaluated by TTE in acute phase
Cardiac injury evaluated by TTE in chronic phase
Time frame: Within 4-8 months after CO exposure
Cardiac injury related to CO poisoning evaluated by TTE in chronic phase
Brain injury evaluated by brain imaging modality related to CO poisoning
Time frame: Within 6 months after CO exposure
Brain injury evaluated by brain MRI in CO poisoning
Brain injury related to CO poisoning
Time frame: Within 6 months after CO exposure
Brain injury evaluated by laboratory tests in CO poisoning
Association between presence of cardiac injury, which is evaluated by cardiac enzyme or cardiac imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 1 month after CO exposure
Time frame: Outcomes at 1 month after CO exposure
Association between presence of cardiac injury, which is evaluated by electrocardiogram, cardiac enzyme, or cardiac imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 1 month after CO exposure
Association between presence of cardiac injury, which is evaluated by cardiac enzyme or cardiac imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 6 months after CO exposure
Time frame: Outcomes at 6 months after CO exposure
Association between presence of cardiac injury, which is evaluated by electrocardiogram, cardiac enzyme, or cardiac imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 6 months after CO exposure
Association between presence of cardiac injury, which is evaluated by cardiac enzyme or cardiac imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 12 months after CO exposure
Time frame: Outcomes at 12 months after CO exposure
Association between presence of cardiac injury, which is evaluated by electrocardiogram, cardiac enzyme, or cardiac imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 12 months after CO exposure
Association between presence of cardiac injury, which is evaluated by cardiac enzyme or cardiac imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 5 years after CO exposure
Time frame: Outcomes at 5 years after CO exposure
Association between presence of cardiac injury, which is evaluated by electrocardiogram, cardiac enzyme, or cardiac imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 5 years after CO exposure
Association between presence of brain injury, which is evaluated by brain imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 1 month after CO exposure evaluated by neurocognitive function tests
Time frame: Outcomes at 1 month after CO exposure
Association between presence of brain injury, which is evaluated by brain MRI, etc, and poor outcome including mortality, and neurocognitive and psychological sequelae at 1 month after CO exposure evaluated by such as GDS or CONSB, etc
Association between presence of brain injury, which is evaluated by brain imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 6 months after CO exposure evaluated by neurocognitive function tests
Time frame: Outcomes at 6 months after CO exposure
Association between presence of brain injury, which is evaluated by brain MRI, etc, and poor outcome including mortality, and neurocognitive and psychological sequelae at 6 months after CO exposure evaluated by such as GDS or CONSB, etc
Association between presence of brain injury, which is evaluated by brain imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 12 months after CO exposure evaluated by neurocognitive function tests
Time frame: Outcomes at 12 months after CO exposure
Association between presence of brain injury, which is evaluated by brain MRI, etc, and poor outcome including mortality, and neurocognitive and psychological sequelae at 12 months after CO exposure evaluated by such as GDS or CONSB, etc
Association between presence of brain injury, which is evaluated by brain imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 5 years after CO exposure evaluated by neurocognitive function tests
Time frame: Outcomes at 5 years after CO exposure
Association between presence of brain injury, which is evaluated by brain MRI, etc, and poor outcome including mortality, and neurocognitive and psychological sequelae at 5 years after CO exposure evaluated by such as GDS or CONSB, etc
Association between presence of brain injury, which is evaluated by laboratory tests, and poor outcome including mortality, and neurocognitive and psychological sequelae at 1 month after CO exposure evaluated by neurocognitive function tests
Time frame: Outcomes at 1 month after CO exposure
Association between presence of brain injury, which is evaluated by laboratory tests, etc, and poor outcome including mortality, and neurocognitive and psychological sequelae at 1 month after CO exposure evaluated by such as GDS or CONSB, etc
Association between presence of brain injury, which is evaluated by laboratory tests, and poor outcome including mortality, and neurocognitive and psychological sequelae at 6 months after CO exposure evaluated by neurocognitive function tests
Time frame: Outcomes at 6 months after CO exposure
Association between presence of brain injury, which is evaluated by laboratory tests, etc, and poor outcome including mortality, and neurocognitive and psychological sequelae at 6 months after CO exposure evaluated by such as GDS or CONSB, etc
Association between presence of brain injury, which is evaluated by laboratory tests, and poor outcome including mortality, and neurocognitive and psychological sequelae at 12 months after CO exposure evaluated by neurocognitive function tests
Time frame: Outcomes at 12 months after CO exposure
Association between presence of brain injury, which is evaluated by laboratory tests, etc, and poor outcome including mortality, and neurocognitive and psychological sequelae at 12 months after CO exposure evaluated by such as GDS or CONSB, etc
Association between presence of brain injury, which is evaluated by laboratory tests, and poor outcome including mortality, and neurocognitive and psychological sequelae at 5 years after CO exposure evaluated by neurocognitive function tests
Time frame: Outcomes at 5 years after CO exposure
Association between presence of brain injury, which is evaluated by laboratory tests, etc, and poor outcome including mortality, and neurocognitive and psychological sequelae at 5 years after CO exposure evaluated by such as GDS or CONSB, etc
Therapeutic response to drugs at 1 month
Time frame: At 1 month after CO exposure
Therapeutic response to additional drug including steroid at 1 month after CO exposure
Therapeutic response to drugs at 6 months
Time frame: At 6 months after CO exposure
Therapeutic response to additional drug including steroid at 6 months after CO exposure
Therapeutic response to drugs at 12 months
Time frame: At 12 months after CO exposure
Therapeutic response to additional drug including steroid at 12 months after CO exposure
Prevalence of poor outcomes including mortality, and neurocognitive and psychological sequelae after CO poisoning at 1 month
Time frame: At 1 month after CO exposure
Prevalence of poor outcomes including mortality, and neurocognitive and psychological sequelae evaluated by, such as GDS or CONSB, etc, after CO poisoning at 1 month after CO exposure
Prevalence of poor outcomes including mortality, and neurocognitive and psychological sequelae after CO poisoning at 6 months
Time frame: At 6 months after CO exposure
Prevalence of poor outcomes including mortality, and neurocognitive and psychological sequelae evaluated by, such as GDS or CONSB, etc, after CO poisoning at 6 months after CO exposure
Prevalence of poor outcomes including mortality, and neurocognitive and psychological sequelae after CO poisoning at 12 months
Time frame: At 12 months after CO exposure
Prevalence of poor outcomes including mortality, and neurocognitive and psychological sequelae evaluated by, such as GDS or CONSB, etc, after CO poisoning at 12 months after CO exposure
Prevalence of poor outcomes including mortality, and neurocognitive and psychological sequelae after CO poisoning at 5 years
Time frame: At 5 years after CO exposure
Prevalence of poor outcomes including mortality, and neurocognitive and psychological sequelae evaluated by, such as GDS or CONSB, etc, after CO poisoning at 5 years after CO exposure
Organ injury related to CO poisoning
Time frame: Within 6 months after CO exposure
Organ injury, such as lung, kidney, liver, pancreas, or bowel, etc, related to CO poisoning
Complications related to CO poisoning
Time frame: Within 6 months after CO exposure
Complications, such as pulmonary thromboembolism or rhabdomyolysis, etc, related to CO poisoning
Effect of HBO for delayed neurocognitive and psychological dysfunction at 1 year after onset
Time frame: Within 1 year after delayed neurocognitive and psychological sequelae onset
Effect of HBO for patient with delayed neurocognitive and psychological sequelae at 1 year after sequelae onset
Effect of HBO for delayed neurocognitive and psychological dysfunction at 2 years after onset
Time frame: Within 2 years after delayed neurocognitive and psychological sequelae onset
Effect of HBO for patient with delayed neurocognitive and psychological sequelae at 2 years after sequelae onset
Validation of methods evaluating neurocognitive and psychological outcomes
Time frame: Within 6 months after CO exposure
Validation of methods evaluating neurocognitive and psychological outcomes within 6 months
Review the complete result tables and limitations in the official record.
Open official results ↗Research locations (1)
The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.
1 locations
Wonju Severance Christian HospitalWŏnju, Gangwon-do, South KoreaRecruiting
Study team and timeline
- Lead sponsor
- Wonju Severance Christian Hospital
- Study start
- Jul 29, 2020 Actual
- Primary completion
- 2030-12 Estimated
- Study completion
- 2035-12 Estimated
- First posted
- Jul 29, 2020 Actual
- Last updated
- Nov 10, 2026 Actual
Official study contacts
Official study title
CARbon monoxidE intoxiCatiOn in Korea: Prospective Cohort (CARE CO Cohort)
Ask Wellness Clinical Research
Your message goes to WCR, including when this study is run by another organization. WCR may offer general guidance but may not operate this trial, have access to its team or be able to enroll you.
Source: ClinicalTrials.gov API v2. Information is submitted by sponsors and investigators. NLM does not approve the safety or science of all listed studies. Registry disclaimer.
Retrieved: Nov 12, 2026 · Last registry update: Nov 10, 2026